Full Text View
Tabular View
No Study Results Posted
Related Studies
A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer
This study is ongoing, but not recruiting participants.
Study NCT00544960   Information provided by Ascenta Therapeutics
First Received: October 12, 2007   Last Updated: July 16, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Non-small Cell Lung Cancer
Additional conditions recognized in this trial
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
More general conditions related to this trial
Carcinoma
Lung Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Interventions listed in this trial
AT-101 and docetaxel
placebo and docetaxel
Additional drug interventions recognized in this trial
Docetaxel
Gossypol
Gossypol acetic acid
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antispermatogenic Agents
Contraceptive Agents
Contraceptive Agents, Female
Contraceptive Agents, Male
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Spermatocidal Agents
Therapeutic Uses
Sponsors listed in this trial
Ascenta Therapeutics


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services